About the Journal
Translational Cancer Research
Aims and scope
Translational Cancer Research (Transl Cancer Res TCR; Print ISSN: 2218-676X; Online ISSN 2219-6803; http://tcr.amegroups.com/) is an Open Access, peer-reviewed journal, indexed in Science Citation Index Expanded (SCIE). TCR publishes laboratory studies of novel therapeutic interventions as well as clinical trials which evaluate new treatment paradigms for cancer; results of novel research investigations which bridge the laboratory and clinical settings including risk assessment, cellular and molecular characterization, prevention, detection, diagnosis and treatment of human cancers with the overall goal of improving the clinical care of cancer patients. The focus of TCR is original, peer-reviewed, science-based research that successfully advances clinical medicine toward the goal of improving patients' quality of life. The editors and an international advisory group of scientists and clinician-scientists as well as other experts will hold TCR articles to the high-quality standards. We accept Original Articles as well as Review Articles, Editorials and Brief Articles.
TCR is an international peer-reviewed journal, published by AME Publishing Company. It is published bimonthly (Jun. 2012 - Aug. 2019), monthly (Sep. 2019 - ) and openly distributed worldwide.
Science Citation Index Expanded (SCIE), 2018 Impact Factor 1.07
➢ Manuscripts Turnaround Time:
External peer review: 1-2 months
Revision time: 2-4 weeks
Publication Ahead of Print: within 1-2 months after being accepted
Formal publication: within 1-3 months after being accepted. Original Articles are listed as priority.
➢ The Official Publication of:
Society for Translational Medicine (STM), Hong Kong